IL120696A - Component b as cicatrizant - Google Patents
Component b as cicatrizantInfo
- Publication number
- IL120696A IL120696A IL12069697A IL12069697A IL120696A IL 120696 A IL120696 A IL 120696A IL 12069697 A IL12069697 A IL 12069697A IL 12069697 A IL12069697 A IL 12069697A IL 120696 A IL120696 A IL 120696A
- Authority
- IL
- Israel
- Prior art keywords
- experiment
- component
- wound
- day
- days
- Prior art date
Links
- 206010052428 Wound Diseases 0.000 claims abstract description 37
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 37
- 230000003902 lesion Effects 0.000 claims abstract description 6
- 230000000472 traumatic effect Effects 0.000 claims abstract description 6
- 208000025865 Ulcer Diseases 0.000 claims abstract description 5
- 231100000397 ulcer Toxicity 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002474 experimental method Methods 0.000 description 65
- 230000029663 wound healing Effects 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 230000000699 topical effect Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 231100000673 dose–response relationship Toxicity 0.000 description 15
- 229940098773 bovine serum albumin Drugs 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 7
- 229960002537 betamethasone Drugs 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001955 cumulated effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- MBGVUMXBUGIIBQ-LEWJYISDSA-N 1-[(3r,4r)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one Chemical compound C([C@H]([C@@H](C1)CO)N2C3=CC=CC=C3N(C2=O)CC)CN1CC1CCCCCCC1 MBGVUMXBUGIIBQ-LEWJYISDSA-N 0.000 description 1
- MGTZNGICWXYDPR-ZJWHSJSFSA-N 3-[[(2r)-2-[[(2s)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]butanoic acid Chemical compound N([C@@H](CC(C)C)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)NC(C)CC(O)=O)C(=O)N1CCCCCC1 MGTZNGICWXYDPR-ZJWHSJSFSA-N 0.000 description 1
- BPPVUXSMLBXYGG-UHFFFAOYSA-N 4-[3-(4,5-dihydro-1,2-oxazol-3-yl)-2-methyl-4-methylsulfonylbenzoyl]-2-methyl-1h-pyrazol-3-one Chemical compound CC1=C(C(=O)C=2C(N(C)NC=2)=O)C=CC(S(C)(=O)=O)=C1C1=NOCC1 BPPVUXSMLBXYGG-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 241001091551 Clio Species 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dental Preparations (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Glass Compositions (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002251356A CA2251356A1 (en) | 1996-04-24 | 1996-04-24 | Component b as cicatrizant |
| PCT/EP1996/001702 WO1997039765A1 (en) | 1996-04-24 | 1996-04-24 | Component b as cicatrizant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL120696A0 IL120696A0 (en) | 1997-08-14 |
| IL120696A true IL120696A (en) | 2001-10-31 |
Family
ID=25680594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12069697A IL120696A (en) | 1996-04-24 | 1997-04-17 | Component b as cicatrizant |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5998364A (es) |
| EP (1) | EP0895478B1 (es) |
| JP (1) | JP3882943B2 (es) |
| AT (1) | ATE234110T1 (es) |
| AU (1) | AU727618B2 (es) |
| CA (1) | CA2251356A1 (es) |
| DE (1) | DE69626691T2 (es) |
| DK (1) | DK0895478T3 (es) |
| EA (1) | EA001077B1 (es) |
| ES (1) | ES2188754T3 (es) |
| IL (1) | IL120696A (es) |
| NO (1) | NO320611B1 (es) |
| WO (1) | WO1997039765A1 (es) |
| ZA (1) | ZA973442B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2336773C (en) * | 1998-07-09 | 2009-12-15 | Applied Research Systems Ars Holding N.V. | Component b as angiogenic agent in combination with human growth factors |
| CA2520029C (en) | 2003-04-16 | 2014-07-15 | Applied Research Systems Ars Holding N.V. | Slurp-1 compositions and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE53166B1 (en) * | 1980-08-05 | 1988-08-03 | Searle & Co | Synthetic urogastrone gene,corresponding plasmid recombinants,transformed cells,production thereof and urogastrone expression |
| IT1257184B (it) * | 1992-12-22 | 1996-01-10 | Applied Research Systems | Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale |
-
1996
- 1996-04-24 US US09/171,659 patent/US5998364A/en not_active Expired - Fee Related
- 1996-04-24 EP EP96914107A patent/EP0895478B1/en not_active Expired - Lifetime
- 1996-04-24 AU AU57605/96A patent/AU727618B2/en not_active Ceased
- 1996-04-24 JP JP50603797A patent/JP3882943B2/ja not_active Expired - Fee Related
- 1996-04-24 DE DE69626691T patent/DE69626691T2/de not_active Expired - Fee Related
- 1996-04-24 DK DK96914107T patent/DK0895478T3/da active
- 1996-04-24 CA CA002251356A patent/CA2251356A1/en not_active Abandoned
- 1996-04-24 WO PCT/EP1996/001702 patent/WO1997039765A1/en not_active Ceased
- 1996-04-24 AT AT96914107T patent/ATE234110T1/de not_active IP Right Cessation
- 1996-04-24 EA EA199800953A patent/EA001077B1/ru not_active IP Right Cessation
- 1996-04-24 ES ES96914107T patent/ES2188754T3/es not_active Expired - Lifetime
-
1997
- 1997-04-17 IL IL12069697A patent/IL120696A/en not_active IP Right Cessation
- 1997-04-22 ZA ZA9703442A patent/ZA973442B/xx unknown
-
1998
- 1998-10-23 NO NO19984965A patent/NO320611B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA199800953A1 (ru) | 1999-04-29 |
| US5998364A (en) | 1999-12-07 |
| DK0895478T3 (da) | 2003-06-23 |
| EP0895478A1 (en) | 1999-02-10 |
| AU5760596A (en) | 1997-11-12 |
| IL120696A0 (en) | 1997-08-14 |
| DE69626691T2 (de) | 2003-08-14 |
| WO1997039765A1 (en) | 1997-10-30 |
| AU727618B2 (en) | 2000-12-14 |
| ES2188754T3 (es) | 2003-07-01 |
| EP0895478B1 (en) | 2003-03-12 |
| ZA973442B (en) | 1998-02-23 |
| JP3882943B2 (ja) | 2007-02-21 |
| CA2251356A1 (en) | 1997-10-30 |
| DE69626691D1 (de) | 2003-04-17 |
| JP2000510436A (ja) | 2000-08-15 |
| NO984965D0 (no) | 1998-10-23 |
| NO984965L (no) | 1998-12-01 |
| NO320611B1 (no) | 2005-12-27 |
| ATE234110T1 (de) | 2003-03-15 |
| EA001077B1 (ru) | 2000-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nanney | Epidermal and dermal effects of epidermal growth factor during wound repair | |
| EP0200757A1 (en) | STIMULATION OF WOUND HEALING WITH THE HUMAN EPIDERMAL GROWTH FACTOR PREPARED FROM RECOMBINANT DNA. | |
| US5155038A (en) | Use of thrombospondin to promote wound healing | |
| US7011965B2 (en) | Compositions and methods for stimulating wound healing and fibroblast proliferation | |
| WO2008037262A1 (en) | Wound healing composition comprising phosphate, iron and copper | |
| JP4102437B2 (ja) | アクチビンおよびインヒビン刺激因子を含有する医薬組成物 | |
| JPH05500356A (ja) | 創傷の治癒 | |
| Wethers et al. | Accelerated healing of chronic sickle-cell leg ulcers treated with RGD peptide matrix. RGD Study Group | |
| JPH04505756A (ja) | 細胞及び組織を再生させる活性を有する薬剤、該薬剤を含有する安定化された組成物及びそれらの治療的、外科的及び美容学的用途 | |
| US5202118A (en) | Method for promoting wound healing using IL-1 | |
| EP0416678B1 (en) | Topical compositions containing Defibrotide | |
| EP1719522B1 (en) | Medicinal composition comprising TCF-II | |
| EP0895478B1 (en) | Component b as cicatrizant | |
| EP0393140B1 (en) | Topical wound-healing preparations comprising interleukin-1 proteins | |
| KR100413844B1 (ko) | 반흔형성제인성분b | |
| EP1234581B1 (en) | Use of secretory leucocyte protease inhibitor for keloid and scars | |
| JPH07316066A (ja) | 創傷治癒剤 | |
| WO1995007710A1 (en) | Remedy for wound | |
| RU2153352C1 (ru) | Фармацевтическая композиция, обладающая ранозаживляющим и противовоспалительным действием | |
| JPH0656692A (ja) | Ｔｃｆ−ｉｉを有効成分とする創傷治療剤 | |
| JPH07215894A (ja) | 創傷治療剤 | |
| HK40091784A (zh) | 治疗伤口的组合物和方法 | |
| KR20230136597A (ko) | 상처 치료를 위한 조성물들 및 방법들 | |
| UA56166C2 (uk) | Компонент в як агент, що рубцює | |
| WO1996016669A1 (en) | Use of human recombinant epidermal growth factor in the manufacture of a medicament for treating acne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |